Anupam Rasayan India Limited US Acquisition Call Decoded: $150M cheque, 9× EBITDA, and a 5–7 year strategy time-travel
1. Opening Hook
Anupam Rasayan didn’t just buy a US company. It bought geography, customers, chemistry, geopolitics—and a lot of investor imagination.
In one call, management connected fluorination in India, polymers in Kansas, semiconductors in the US, EVs, aviation, Biosecure Act, China Plus One (but not really), and still claimed discipline in capital allocation. Bold.
Jayhawk Fine Chemicals is not a “let’s try something abroad” experiment. This is a full-on statement: we want to be a global CDMO and specialty platform.
The best part? Management openly admits this deal moves Anupam’s strategy 5–7 years forward. The risky part? Execution across continents is never PowerPoint-friendly.
Read on—because this call was less about numbers and more about ambition with a balance sheet attached.
2. At a Glance
Acquisition Value ~$150M – Paid calmly, no banker-induced panic.
Jayhawk Revenue ~$78M (CY24) – Solid, not flashy, but dependable.
EBITDA Margin ~19% – Lower than Anupam’s, but not embarrassing.
EV/EBITDA ~9× – Not cheap, not reckless, very CDMO-like.
EPS Accretive Day One – Management’s favourite sentence in the call.
3. Management’s Key Commentary
“This acquisition is fully aligned with our long-term strategy.” (Translation: This wasn’t a last-minute overseas shopping trip 😏)
“Jayhawk gives us an onshore US manufacturing presence.” (Translation: Customers like ‘Made in USA’ more than Zoom calls.)
“This strengthens our performance materials portfolio.” (Translation: Less agro cyclicality, more semicon bragging rights.)
“Our strategy advances by 5–7 years.” (Translation: We paid to skip the painful approval queue 🚀)
“The deal is EPS accretive from day one.” (Translation: Please don’t ask dilution questions.)
“China Plus One is not our strategy, strength is.” (Translation: We’ll happily benefit, but won’t say it loudly.)
